Featuring a patient’s perspective on the Health Research Authority’s transparency consultation, the launch of the Journal of Trial and Error and the call for ResearchGate to educate users on responsible content sharing.
Featuring the use of ‘spin’ in clinical trial abstracts, the first publication in UCL Open: Environment, a new clinical trial educational resource and insights from the OASPA webinar on learned societies and open access.
The Association of the British Pharmaceutical Industry (ABPI) has said that it wants to take transparency to the next level, and has committed to making clinical research more accessible and understandable across the pharmaceutical industry.
Featuring the release of the AMWA-EMWA-ISMPP position statement on predatory publishing, the hidden disclosures of medical journal editors, the citation advantage of preprints and the launch of the Open Pharma Calendar of Open Access Events
Featuring the lack of transparency across clinical trials in French hospitals, the introduction of Registered Reports, the data detective who protects patients and one patient advocate’s experience with the medical publishing process
Evidence is essential for identifying treatment priorities and developing polices, said Claire Allen of Evidence Aid, at Evidence-Based Medicine Live (EBMLive), which took place on 15–17 July in Oxford, UK.
At a workshop on managing conflicts of interest in medicine, Chris Winchester, CEO of Oxford PharmaGenesis and co-founder of Open Pharma, argued for openness.
Featuring a summary of the Open Pharma team’s trip to Evidence-Based Medicine Live 2019, the potential use of Literature Programming to improve research transparency, a new data depot project in India and the lack of institutional incentives for researchers to publish open access
When it comes to driving change in academic publishing practices, much of the focus is on making research outputs freely available to all those who wish to access them. However, open access publishing is just the tip of the iceberg.
Featuring the latest results from the Good Pharma Scorecard, the newest signatories to DORA, incentives for sharing data and potential barriers to mandating open access.